Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Lowe

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Clinical Immunology (Orlando, Fla.)|February 5, 2022
Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficienciesKlaus Warnatz, Stephen Jolles, Carlo Agostini, et al.
Journal of Leukocyte Biology|October 16, 2024
A new model measuring bacterial phagocytosis and phagolysosomal oxidation in humans using the intradermal injection of methylene blue-labeled Escherichia coliGeorge B Collins, Jhonatan de Souza Carvalho, Sandali C Jayasinghe, et al.
British Journal of Clinical Pharmacology|March 23, 2026
Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19Akosua A Agyeman, Laura Buggiotti, Li-An K Brown, et al.
The Lancet. Infectious Diseases|August 19, 2021
Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trialsEd Moran, Tim Cook, Anna L Goodman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2017
Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory SyndromeJustine K Nakiwala, Naomi F Walker, Collin R Diedrich, et al.
Iscience|March 2, 2026
Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised hostJosé Afonso Guerra-Assunção, Ruairi McErlean, Katie Townsend, et al.
Journal of Clinical Immunology|May 6, 2023
Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient PatientsMichele Chan, Me Me Nay Linn, Thomas O'Hagan, et al.
The Journal of Infectious Diseases|April 1, 2025
A viro-immunological model to characterize the antiviral effect of molnupiravir in SARS-CoV-2-infected outpatients: implication for treatment durationBach Tran Nguyen, Julie Bertrand, Akosua A Agyeman, et al.
Frontiers in Immunology|August 28, 2020
Altered Microbiota, Impaired Quality of Life, Malabsorption, Infection, and Inflammation in CVID Patients With DiarrhoeaCornelia M van Schewick, Christina Nöltner, Svenja Abel, et al.
The Journal of Clinical Investigation|September 11, 2025
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2Shadisadat Esmaeili, Katherine Owens, Ugo Avila-Ponce de Leon, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Clinical Immunology (Orlando, Fla.)|February 5, 2022
Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficienciesKlaus Warnatz, Stephen Jolles, Carlo Agostini, et al.
Journal of Leukocyte Biology|October 16, 2024
A new model measuring bacterial phagocytosis and phagolysosomal oxidation in humans using the intradermal injection of methylene blue-labeled Escherichia coliGeorge B Collins, Jhonatan de Souza Carvalho, Sandali C Jayasinghe, et al.
British Journal of Clinical Pharmacology|March 23, 2026
Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19Akosua A Agyeman, Laura Buggiotti, Li-An K Brown, et al.
The Lancet. Infectious Diseases|August 19, 2021
Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trialsEd Moran, Tim Cook, Anna L Goodman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2017
Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory SyndromeJustine K Nakiwala, Naomi F Walker, Collin R Diedrich, et al.
Iscience|March 2, 2026
Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised hostJosé Afonso Guerra-Assunção, Ruairi McErlean, Katie Townsend, et al.
Journal of Clinical Immunology|May 6, 2023
Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient PatientsMichele Chan, Me Me Nay Linn, Thomas O'Hagan, et al.
The Journal of Infectious Diseases|April 1, 2025
A viro-immunological model to characterize the antiviral effect of molnupiravir in SARS-CoV-2-infected outpatients: implication for treatment durationBach Tran Nguyen, Julie Bertrand, Akosua A Agyeman, et al.
Frontiers in Immunology|August 28, 2020
Altered Microbiota, Impaired Quality of Life, Malabsorption, Infection, and Inflammation in CVID Patients With DiarrhoeaCornelia M van Schewick, Christina Nöltner, Svenja Abel, et al.
The Journal of Clinical Investigation|September 11, 2025
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2Shadisadat Esmaeili, Katherine Owens, Ugo Avila-Ponce de Leon, et al.
Pageof 10